CTSO
Cytosorbents Corp
NASDAQ · Healthcare · Medical - Devices · US
$4.26
−6.17%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$4.68
From 52W high−74.55%
Volume4021.00
Market cap$13.39M
P/E (TTM)—
P/S (TTM)0.4x
Div yield—
Key dataNov 4, 2026
Open
$4.68
From 52W high
−74.55%
Volume
4021.00
Market cap
$13.39M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.5x
P/E (TTM)
—
RSI (14)
46.4
MomentumView details →
1D Return
−6.17%
YTD Return
−66.20%
SummaryUpdated Jun 1, 2026
CytoSorbents Corporation (NASDAQ:CTSO) is a medical device company founded in 1997 and headquartered in Princeton, New Jersey. The company specializes in blood purification technology, developing and commercializing medical devices that remove harmful substances from blood during critical care situations. Originally incorporated as MedaSorb Technologies Corporation, the company changed its name to CytoSorbents Corporation in May 2010 and went public in 2006. Today, CytoSorbents operates primarily in international markets with over 270,000 of its flagship devices used across 70+ countries, while pursuing regulatory approval to enter the lucrative U.S. healthcare market.
Similar companies
Latest newsMore news →
Cytosorbents Corp announced that it will report its third-quarter 2026 financial results and recent business highlights after the market close on November 12, 2026.6d agoCytoSorbents Corporation announced upcoming data presentations on the use of CytoSorb in open heart surgery at the EACTS Annual Meeting in Barcelona and in critical care at the ESICM Annual Congress in Lisbon in October 2026.35d ago